So approximately 2 years ago the drug company Biogen put into stage III trials their new monoclonal antibody focused on plaque build up of a certain type in Alzheimer's. Their hope obviously was to augment plaque production to change the progression of Alzheimer's Dementia. Well about a year ago, they all but abandoned the drug as the clinical findings were that there was no significant change in the progression of the awful disease.
Well apparently the data was reviewed and secondary endpo